Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.46
HSP's Cash to Debt is ranked higher than
59% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. HSP: 0.46 )
HSP' s 10-Year Cash to Debt Range
Min: 0.11   Max: No Debt
Current: 0.46

Equity to Asset 0.50
HSP's Equity to Asset is ranked higher than
62% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. HSP: 0.50 )
HSP' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.69
Current: 0.5

0.34
0.69
Interest Coverage 6.04
HSP's Interest Coverage is ranked higher than
54% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. HSP: 6.04 )
HSP' s 10-Year Interest Coverage Range
Min: 0.19   Max: 9999.99
Current: 6.04

0.19
9999.99
F-Score: 7
Z-Score: 4.40
M-Score: -2.77
WACC vs ROIC
11.00%
9.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.45
HSP's Operating margin (%) is ranked higher than
78% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. HSP: 10.45 )
HSP' s 10-Year Operating margin (%) Range
Min: 0.41   Max: 16.17
Current: 10.45

0.41
16.17
Net-margin (%) 7.46
HSP's Net-margin (%) is ranked higher than
76% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.01 vs. HSP: 7.46 )
HSP' s 10-Year Net-margin (%) Range
Min: -0.23   Max: 11.4
Current: 7.46

-0.23
11.4
ROE (%) 10.41
HSP's ROE (%) is ranked higher than
82% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. HSP: 10.41 )
HSP' s 10-Year ROE (%) Range
Min: -0.31   Max: 24.74
Current: 10.41

-0.31
24.74
ROA (%) 5.23
HSP's ROA (%) is ranked higher than
79% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. HSP: 5.23 )
HSP' s 10-Year ROA (%) Range
Min: -0.16   Max: 13.13
Current: 5.23

-0.16
13.13
ROC (Joel Greenblatt) (%) 17.24
HSP's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.87 vs. HSP: 17.24 )
HSP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 0.67   Max: 53.84
Current: 17.24

0.67
53.84
Revenue Growth (3Y)(%) 2.20
HSP's Revenue Growth (3Y)(%) is ranked higher than
67% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. HSP: 2.20 )
HSP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -0.9   Max: 12.4
Current: 2.2

-0.9
12.4
EBITDA Growth (3Y)(%) 29.60
HSP's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. HSP: 29.60 )
HSP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -32.7   Max: 29.6
Current: 29.6

-32.7
29.6
» HSP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

HSP Guru Trades in Q1 2014

Jim Simons 151,800 sh (+284.30%)
Mario Gabelli 153,770 sh (+30.68%)
Vanguard Health Care Fund 8,375,170 sh (+22.69%)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Richard Snow Sold Out
Brian Rogers Sold Out
Jeff Auxier 205,530 sh (-5.75%)
John Rogers 4,127,850 sh (-11.62%)
Paul Tudor Jones 10,800 sh (-26.41%)
Steven Cohen 17,130 sh (-55.51%)
» More
Q2 2014

HSP Guru Trades in Q2 2014

Mario Gabelli 204,370 sh (+32.91%)
Jim Simons 182,900 sh (+20.49%)
Vanguard Health Care Fund 8,375,170 sh (unchged)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Jeff Auxier 181,463 sh (-11.71%)
John Rogers 3,130,809 sh (-24.15%)
Paul Tudor Jones 7,700 sh (-28.70%)
» More
Q3 2014

HSP Guru Trades in Q3 2014

Joel Greenblatt 313,242 sh (New)
Paul Tudor Jones 24,894 sh (+223.30%)
Jim Simons 323,100 sh (+76.65%)
Mario Gabelli 254,870 sh (+24.71%)
Michael Price 400,000 sh (unchged)
Vanguard Health Care Fund 8,375,170 sh (unchged)
Robert Bruce 10,000 sh (unchged)
John Rogers 2,433,369 sh (-22.28%)
Jeff Auxier 127,307 sh (-29.84%)
» More
Q4 2014

HSP Guru Trades in Q4 2014

Jim Simons 631,695 sh (+95.51%)
Mario Gabelli 352,370 sh (+38.25%)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Joel Greenblatt Sold Out
Jeff Auxier 126,907 sh (-0.31%)
Vanguard Health Care Fund 7,966,970 sh (-4.87%)
John Rogers 2,311,309 sh (-5.02%)
Paul Tudor Jones 19,798 sh (-20.47%)
» More
» Details

Insider Trades

Latest Guru Trades with HSP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 45.10
HSP's P/E(ttm) is ranked higher than
77% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 52.50 vs. HSP: 45.10 )
HSP' s 10-Year P/E(ttm) Range
Min: 8.48   Max: 133.97
Current: 45.1

8.48
133.97
Forward P/E 27.10
HSP's Forward P/E is ranked higher than
81% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 61.73 vs. HSP: 27.10 )
N/A
PE(NRI) 45.10
HSP's PE(NRI) is ranked higher than
78% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 51.50 vs. HSP: 45.10 )
HSP' s 10-Year PE(NRI) Range
Min: 8.48   Max: 135
Current: 45.1

8.48
135
P/B 4.50
HSP's P/B is ranked higher than
64% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. HSP: 4.50 )
HSP' s 10-Year P/B Range
Min: 1.52   Max: 5.83
Current: 4.5

1.52
5.83
P/S 3.36
HSP's P/S is ranked higher than
71% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.38 vs. HSP: 3.36 )
HSP' s 10-Year P/S Range
Min: 0.99   Max: 3.4
Current: 3.36

0.99
3.4
PFCF 64.50
HSP's PFCF is ranked higher than
81% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1165.60 vs. HSP: 64.50 )
HSP' s 10-Year PFCF Range
Min: 8.32   Max: 203.78
Current: 64.5

8.32
203.78
POCF 22.83
HSP's POCF is ranked higher than
84% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.96 vs. HSP: 22.83 )
HSP' s 10-Year POCF Range
Min: 5.95   Max: 50.76
Current: 22.83

5.95
50.76
EV-to-EBIT 34.29
HSP's EV-to-EBIT is ranked higher than
78% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.80 vs. HSP: 34.29 )
HSP' s 10-Year EV-to-EBIT Range
Min: -1403.5   Max: 508.2
Current: 34.29

-1403.5
508.2
Shiller P/E 75.40
HSP's Shiller P/E is ranked higher than
74% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.82 vs. HSP: 75.40 )
HSP' s 10-Year Shiller P/E Range
Min: 12.55   Max: 75.4
Current: 75.4

12.55
75.4
Current Ratio 2.27
HSP's Current Ratio is ranked higher than
71% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. HSP: 2.27 )
HSP' s 10-Year Current Ratio Range
Min: 2.05   Max: 3.03
Current: 2.27

2.05
3.03
Quick Ratio 1.40
HSP's Quick Ratio is ranked higher than
66% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. HSP: 1.40 )
HSP' s 10-Year Quick Ratio Range
Min: 1.2   Max: 2.01
Current: 1.4

1.2
2.01
Days Inventory 144.51
HSP's Days Inventory is ranked higher than
71% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.83 vs. HSP: 144.51 )
HSP' s 10-Year Days Inventory Range
Min: 47.38   Max: 139.51
Current: 144.51

47.38
139.51
Days Sales Outstanding 49.22
HSP's Days Sales Outstanding is ranked higher than
87% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. HSP: 49.22 )
HSP' s 10-Year Days Sales Outstanding Range
Min: 43.91   Max: 59.38
Current: 49.22

43.91
59.38

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 7.00
HSP's Price/Tangible Book is ranked higher than
62% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. HSP: 7.00 )
HSP' s 10-Year Price/Tangible Book Range
Min: 3.04   Max: 20.95
Current: 7

3.04
20.95
Price/DCF (Projected) 3.10
HSP's Price/DCF (Projected) is ranked higher than
82% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.70 vs. HSP: 3.10 )
HSP' s 10-Year Price/DCF (Projected) Range
Min: 0.91   Max: 2.2
Current: 3.1

0.91
2.2
Price/Median PS Value 1.70
HSP's Price/Median PS Value is ranked higher than
63% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. HSP: 1.70 )
HSP' s 10-Year Price/Median PS Value Range
Min: 0.61   Max: 1.35
Current: 1.7

0.61
1.35
Price/Graham Number 3.80
HSP's Price/Graham Number is ranked higher than
75% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.78 vs. HSP: 3.80 )
HSP' s 10-Year Price/Graham Number Range
Min: 2.02   Max: 3.97
Current: 3.8

2.02
3.97
Earnings Yield (Greenblatt) 2.90
HSP's Earnings Yield (Greenblatt) is ranked higher than
75% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. HSP: 2.90 )
HSP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 10
Current: 2.9

0.2
10
Forward Rate of Return (Yacktman) -4.62
HSP's Forward Rate of Return (Yacktman) is ranked higher than
64% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.09 vs. HSP: -4.62 )
HSP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.4   Max: 18.4
Current: -4.62

-1.4
18.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:HOS.Germany,
Hospira, Inc. was incorporated in Delaware on September 16, 2003. The Company is a provider of injectable drugs and infusion technologies. Its portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management products. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. The Company conducts operations and is managed in three reportable segments: Americas; Europe, Middle East and Africa; and Asia Pacific. The Americas segment includes the United States, Canada and Latin America; the EMEA segment includes Europe, the Middle East and Africa; and the APAC segment includes Asia, Japan, Australia and New Zealand. The Company offers Specialty injectable pharmaceutical, Medication management & other pharmaceuticals. The Company's specialty injectable pharmaceutical product category mainly consists of generic injectable pharmaceuticals. These products provide customers with a lower-cost alternative to branded products, when the patent protection has expired, when patents have been declared invalid, or when the products do not infringe the patents of others. These drugs' therapeutic areas include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other areas. The Company's other pharmaceuticals mainly consist of large volume I.V. solution, nutritional and contract manufacturing services. The Company offers infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for the washing and cleansing of wounds or surgical sites. Its contract manufacturing services are offered through its One2One(SM) services group. The Company's medication management products include electronic drug delivery pumps, safety software and disposable administration sets dedicated to the company's pumps. These sets are used to deliver I.V. fluids and medications. Medication management includes TheraDoc, Inc. products, which are module-based clinical surveillance systems that provide patient safety surveillance and clinical decision support. Medication management also includes gravity administration sets and other device products, including needlestick safety products and programs to support Hospira's customers. The Company's main customers in the Americas segment include hospitals, wholesalers, integrated delivery networks and alternate site facilities. Its main customers in the EMEA and APAC segments are hospitals and wholesalers that serve through its own sales force and its distributors. In the U.S., the Company's products are mainly distributed through a network of Company-operated distribution facilities and third-party logistics providers. The Company's competitors in specialty injectable pharmaceuticals in the Americas segment include Baxter International Inc., Bedford Laboratories, Fresenius Kabi, Pfizer, Sandoz
» More Articles for NYSE:HSP

Headlines

Articles On GuruFocus.com
Weekly 52-Week Highs Highlight: SIAL, GIS, TJX, HSP Mar 30 2015 
Hospira’s Q4 Earnings Were Bright, Though Acquisition Is In The Cards Feb 19 2015 
Analysts Weigh in on Pfizer Following Acquisition Announcement of Hospira Feb 06 2015 
Feeling Good With This Med Company Jan 20 2015 
Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
Weekly CFO Sells Highlight: Hospira Inc, Rockwood Holdings Inc, Mylan Inc. Nov 30 2014 
Jeff Auxier Second Quarter Shareholder Letter Aug 08 2014 
Brian Rogers' T. Rowe Price Equity Income Fund Semi-Annual Report 2013 Dec 02 2013 
Ariel Capital's John Rogers Trims Sotheby’s, DeVry, Hospira, IPG, Others Nov 18 2013 
Five Companies Cut - Pzena Investment Management Update Nov 12 2013 


More From Other Websites
These 10 S&P 500 Stocks Were the Best Performers in the First Quarter Apr 01 2015
U.S. Drugmakers Facing First Wave Of Biosimilars Apr 01 2015
Our Take on the First Quarter Apr 01 2015
Cramer: Problem feeding all investing decisions now Mar 31 2015
How Actavis and Allergan Merger May Boost Branded Business Mar 31 2015
Biogen's Biosimilar Version of Remicade Under EU Review - Analyst Blog Mar 31 2015
Zimmer-Biomet Deal Gets European Commission's Approval - Analyst Blog Mar 31 2015
Zimmer Unveils External Fixation System, Expands in Trauma - Analyst Blog Mar 30 2015
Busiest Day for Health-Care Deals Is Set to Spawn More: Real M&A Mar 30 2015
Hospira's INFLECTRA™ (Infliximab) Now Available in Canada Mar 30 2015
Hospira's INFLECTRA™ (Infliximab) Now Available in Canada Mar 30 2015
Hospira's INFLECTRA™ (Infliximab) Now Available in Canada Mar 30 2015
11:30 am Hospira announces the availability of INFLECTRA (infliximab) in Canada, the country's first... Mar 30 2015
Hospira Presents Data on Retacrit, an Epogen Biosimilar - Analyst Blog Mar 30 2015
The Best Performing Stocks of 2015 in the S&P 500 Mar 29 2015
Hyperion Could Be Next Pharma Target With Orphan Drugs: Real M&A Mar 28 2015
The Pharmacyclics–AbbVie Merger: What Are the Details? Mar 28 2015
Neogen Lags Q3 Earnings & Revenue Estimates, Stock Down - Analyst Blog Mar 27 2015
Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And... Mar 27 2015
Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And... Mar 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK